drugset / Trial / NCT05930457
Study of 64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors
Phase 1
Completed
15 enrolled
The First Affiliated Hospital of Guangzhou Medical University
Sinotau Pharmaceutical Group · collab
NaSingle-groupOpen-labelDiagnostic
Summary
This is the study of 64Cu-FAPI-XT117, which is an prospective, single-arm phase I clinical study.
Timeline
- Start
- 2023-07-26
- Primary completion
- 2023-10-31
- Completion
- 2023-12-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 64Cu-FAPI-XT117 | Unknown | — | Other |